Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 5/20 | 0.57 |
| ▸ | ABL1 | P00519 | 4/20 | 0.57 |
| ▸ | FYN | P06241 | 3/20 | 0.48 |
| ▸ | KDR | P35968 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | LCK | P06239 | 2/20 | 0.48 |
| ▸ | LYN | P07948 | 2/20 | 0.48 |
| ▸ | BLK | P51451 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.48 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.48 |
| ▸ | YES1 | P07947 | 1/20 | 0.48 |
| ▸ | HCK | P08631 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | FGR | P09769 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | PRKACA | P17612 | 1/20 | 0.48 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30387175 | 0.87 | PIK3CD (0.55) | SRCABL1KDREGFRHCK | |
| SCHEMBL8318622 | 0.85 | SRC (0.44) | SRCABL1FYNKDRCYP1A2 | |
| SCHEMBL11325 | 0.84 | PIK3CG (0.49) | SRCABL1KDREGFRHCK | |
| SCHEMBL3782102 | 0.84 | PIK3CD (0.57) | SRCABL1FYNKDRCYP1A2 | |
| SCHEMBL15613778 | 0.84 | PIK3CD (0.42) | SRCABL1KDRCYP1A2LCK | |
| SCHEMBL5065122 | 0.84 | PIK3CD (0.57) | SRCABL1KDRLCKEGFR | |
| SCHEMBL408618 | 0.83 | PIK3CD (0.55) | SRCABL1KDRLCKEGFR | |
| SCHEMBL23917208 | 0.80 | MAP2K4 (0.48) | SRCABL1FYNKDRLYN | |
| SCHEMBL5088174 | 0.80 | PIK3CD (0.60) | SRCABL1FYNKDRCYP1A2 | |
| SCHEMBL12123445 | 0.80 | PIK3CD (0.39) | SRCABL1FYNKDRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844038-B2 | 1,2-dithiolane compounds useful in neuroprotection, autoimmune and cancer diseases and conditions | SABILA BIOSCIENCES LLC (US) | 2020-11-24 | — | — | US | disclosed |
| US-10844038-B2 | 1,2-dithiolane compounds useful in neuroprotection, autoimmune and cancer diseases and conditions | SABILA BIOSCIENCES LLC (US) | 2020-11-24 | — | — | US | disclosed |
| US-9580427-B2 | Kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580427-B2 | Kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580427-B2 | Kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-02-28 | — | — | US | disclosed |
| US-20140323464-A1 | KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-30 | — | — | US | disclosed |
| US-20140323464-A1 | KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-30 | — | — | US | disclosed |
| US-20140323464-A1 | KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-30 | — | — | US | disclosed |
| EP-2710007-A2 | KINASE INHIBITORS | The Regents of the University of California (US) | 2014-03-26 | — | — | EP | disclosed |
| WO-2012158843-A2 | KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012158843-A2 | KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-11-22 | — | — | WO | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| EP-2217239-A2 | MODULATION OF PROTEIN TRAFFICKING | Foldrx Pharmaceuticals, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009062118-A2 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323464-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | SRC 87/4885ABL1 23/4885FYN 404/4885 |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | RAB1A, COPB1, GOLT1B | SRC 1332/4885ABL1 1725/4885FYN 950/4885 |
| US-10844038-B2 | 1,2-dithiolane compounds useful in neuroprotection, autoimmune and cancer diseases and conditions | BTK, FYN, YES1 | SRC 13/4885ABL1 296/4885FYN 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.